1
EXHIBIT 10.56
AMENDED AND RESTATED MASOPRACOL LICENSE AGREEMENT
THIS AMENDED AND RESTATED MASOPRACOL LICENSE AGREEMENT ("Agreement") is
made as of the ___ day of April, 1997 (the "Effective Date") by and between
Shaman Pharmaceuticals, Inc., a California corporation, with its principal place
of business at ▇▇▇ ▇▇▇▇ ▇▇▇▇▇ ▇▇▇▇▇▇, ▇▇▇▇▇ ▇▇▇ ▇▇▇▇▇▇▇▇▇, ▇▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇
(hereinafter referred to as "Shaman") and Access Pharmaceuticals, Inc., a
Delaware corporation with its principal place of business at ▇▇▇▇ ▇▇▇▇▇▇▇▇
▇▇▇▇▇▇▇, ▇▇▇▇▇ ▇▇▇, ▇▇▇▇▇▇, ▇▇▇▇▇ ▇▇▇▇▇-▇▇▇▇ (hereinafter referred to as
"Access").
WHEREAS, Shaman and Access previously entered into a Masopracol License
Agreement (the "Prior Agreement") dated as of March 19, 1997, pursuant to which
Access granted Shaman certain rights to reference an Access NDA filing and to
use Masopracol and its analogues for research purposes;
WHEREAS, the parties now desire to amend and restate the Prior
Agreement in order to grant Shaman the right (as contemplated by Section 1.02 of
the Prior Agreement) to make, use and sell Products incorporating Access
intellectual property rights as hereinafter set forth;
WHEREAS, Access owns or has licensed rights in certain pre-clinical
data, including rights to the Actinex(TM) New Drug Application ("NDA") and
associated Drug Master File ("DMF") on file at the U.S. Food and Drug
Administration ("FDA"), information relating to CHX 100, and Access Technology
and Patent Rights (as defined below) relating to Masopracol and the synthesis of
nordihydroguaiaretic acid ("NDGA") and their analogs;
WHEREAS, Shaman desires to secure a license to use such information,
Access Technology and Patent Rights for reference and research and development
purposes, and to produce, use and sell Licensed Products (as defined below), for
use in diabetes and related disease (the "Field") under the terms and conditions
set forth herein; and
NOW THEREFORE, for and in consideration of the covenants, conditions,
and undertakings hereinafter set forth, it is agreed by and between the parties
as follows:
1. Definitions.
1.1 "Affiliate" means: (i) any corporation, firm, partnership or
other entity which directly or indirectly owns, is owned by or is under common
ownership with a party, to the extent of at least fifty percent (50%) of the
equity (or such lesser percentage which is the maximum allowed to be owned of a
foreign corporation in a particular jurisdiction) having the power to vote on or
direct the affairs of the entity, and (ii) any person, firm, partnership,
----
*Certain confidential information has been omitted and filed
separately with the Securities and Exchange Commission.
2
corporation or other entity actually controlled by, controlling or under common
control with a party.
1.2 "Access Information" means the information contained in the NDA
and the DMF and the studies, reports, applications, submissions and other
information owned by or licensed to Access listed in Exhibit A hereto.
1.3 "Access Technology" means any unpublished research and
development information, unpatented inventions, know-how, and technical data in
the possession of Access which relates to and is necessary for the practice of
the Patent Rights in the Field and which Access has the right to provide to
Shaman.
1.4 "Licensed Products" means any method, procedure, process,
product, or component part thereof developed for use in the Field which is
developed through the Access Information or Access Technology or as to which the
right to make, use or sell such Licensed Product would, but for the licenses
granted herein, infringe a valid Patent Right or which contains Masopracol or
NDGA and their analogs (as defined below).
1.5 "Licensed Territory" means the world.
1.6 "Patent Rights" means all rights of Access to any subject matter
described by, claimed in or covered by United States Patent Nos. 4,954,659
titled "1.4-Bis (Dihydroxyphenyl;" 4,774,229 titled "Modification of Plant
Extracts from Zygophyllaceae and Pharmaceutical Use Thereof;" and 4,562,298
titled "Methods of Synthesis of Optically Active Nordihydroguaiaretic Acid and
Intermediates," any improvements, continuations, continuations- in-part,
divisions and substitutions thereof, and any foreign patents corresponding
thereto, and/or any divisions, continuations, or reissue thereof.
1.7 "Net Sales" means the aggregate amount invoiced by Shaman
(including by its Affiliates, licensees and sublicensees) for or on account of
any sale to a non-affiliated purchaser of Licensed Products, less (i) normal and
customary trade discounts (i.e., consistent with customary practice for a
situation in which the Licensed Product is the only product being transferred
between seller and purchaser) allowed and taken, (ii) rebates to wholesalers,
(iii) returns, (iv) amounts for transportation and shipping charges to
purchasers if invoiced separately and paid by Shaman, and (v) taxes (not
including any taxes on income) and duties levied on such sale. Any commercial
use or sale of a Licensed Product at a reduced or promotional price by Shaman
(including its Affiliates, licensees and sublicensees) shall be consistent with
customary trade practices. Notwithstanding anything to the contrary herein,
Licensed Products shall be considered sold when paid.
1.8 "Valid Claim" means a claim of an issued, unexpired patent which
has not been: held invalid or unenforceable by a final decision of a court or
governmental agency of competent jurisdiction, which decision is unappealable or
was not appealed within the
2.
3
time allowed therefor; or admitted in writing to be invalid or unenforceable by
the holder(s) pursuant to a reissue, disclaimer or otherwise.
2. Grant of Licenses.
2.1 Subject to the terms and conditions of this Agreement, Access
grants Shaman and its Affiliates: (i) an exclusive worldwide right and license,
with the right to sublicense subject to Access' prior written approval, which
approval shall not be unreasonably withheld, to use and exploit with the Field
the Access Information (including the Masopracol pre-clinical data and the right
to reference the Actinex NDA)) for reference and research and development
purposes; (ii) an exclusive, worldwide right and license, with the right to
sublicense, to use and exploit within the Field Access Technology, and to make,
use and sell Licensed Products in the Field incorporating, made using or derived
from Access Technology, upon the terms and conditions of this Agreement; and
(iii) an exclusive, worldwide license, with the right to sublicense, under the
Patent Rights to make, use and sell Licensed Products within the Field, to
practice any process, method or procedure covered by, and otherwise exploit, the
Patent Rights within the Field, upon the terms and conditions set forth herein.
2.2 Access shall, except to the extent that it has already done so,
on the Effective Date, promptly disclose to Shaman the Access Information and
provide Shaman with copies of the physical embodiments thereof, and, on the IND
Filing Date, promptly disclose to Shaman the Access Technology and provide
Shaman with copies of the physical embodiments thereof. Access shall provide
Shaman with reasonable assistance in understanding and implementing the Access
Information and the Access Technology. Shaman shall not disclose any unpublished
Access Information or Access Technology furnished by Access pursuant to this
Agreement to third parties during the term of this Agreement or any time
thereafter, provided, however, that Shaman may disclose any such Access
Information or Access Technology at any time: (1) with the prior written consent
of Access, (2) after the same shall have become public through no fault of
Shaman or (3) to sublicensees of Shaman or other persons or entities with whom
Shaman proposes to enter into a business relationship, provided that such
sublicensee or third party enters into a confidentiality agreement reasonably
calculated to maintain the confidentiality of such Access Information and Access
Technology. This Section 2.2 shall not restrict Shaman's right to sell and
promote Licensed Products.
2.3 Access shall, upon Shaman's request, promptly notify the FDA in
writing of Shaman's right to reference the ActinexTM NDA and DMF pursuant to
this Agreement. Access shall promptly provide Shaman with a copy of such written
notification to the FDA, as well as a copy of any responses thereto.
2.4 Access shall, within 90 days of the Effective Date, secure and
promptly provide written confirmation of Shaman's right to purchase its
requirements of Masopracol during the term of this Agreement from Western
Engineering and Research Corporation.
3.
4
2.5 Access shall promptly disclose to Shaman all pre-clinical data
requested by Shaman that is in Access' possession and any other information
related to the synthesis of Masopracol and its analogues which is from time to
time requested by Shaman. Shaman and any development partners or sublicensee
will limit disclosure of all exchanged information to only those of its
officers, employees and consultants who are bound by appropriate obligations to
maintain the confidentiality of such data and information.
3. License Fee and Royalties.
3.1 Shaman has previously paid to Access as a license issue fee One
Hundred and Thirty-Seven Thousand Five Hundred Dollars ($137,500) upon the
execution of the Prior Agreement. Upon execution of this Amendment, Shaman shall
pay to Access Fifty Thousand Dollars ($50,000). In addition, Shaman shall pay to
Access the following milestone payments: (a) [ * ] Dollars [ * ] on [ * ]; (b)
[ * ] Dollars [ * ] on [ * ]; and (c) [ * ] Dollars [ * ] within [ * ] of [ * ]
for a therapeutic use of Masopracol or a synthetic analogue in the Field with
the FDA.
3.2 Shaman shall, with respect to each Licensed Product in each
country of sale until the later of (i) ten (10) years after the date such
Licensed Product is first commercialized; or (ii) the date of expiration of the
last valid patent covering the manufacture, sale or use of such Licensed Product
in such country, pay to Access a royalty in U.S. dollars at the rate of [ * ] of
Net Sales of Licensed Products as earned royalties, provided that such Licensed
Products are covered by a Valid Claim in the country in which, and at the time,
they are sold.
4. Timing of Royalty Payments; Records.
4.1 Within forty-five (45) days after the end of each calendar
quarter, Shaman shall pay to Access the royalty payment due for such quarter in
U.S. dollars without deduction of exchange collection, taxes or other fees that
may be imposed by any government. Such royalties shall be converted, where
applicable, from the currency of the country in which the sale was made into
U.S. dollars at the volume adjusted average exchange rate for such quarter as
published by The Wall Street Journal. Late payments to bear interest at prime
plus 2%).
4.2 Together with each quarterly royalty payment, Shaman shall
submit to Access a written accounting showing its computation of royalties due
under this Agreement for such quarter. Said accounting shall set forth gross
sales, Net Sales, the exchange rate applied, if any, and the total royalties due
for the quarter in question.
4.3 Shaman shall keep full and accurate books and records reflecting
the sales of Licensed Products and the data used in arriving at Net Sales and
the amount of royalties payable to Access hereunder for no less than three years
after the end of each such
----
*Certain confidential information on this page has been omitted and filed
separately with the Securities and Exchange Commission.
4.
5
quarter. Shaman shall permit Access, at Access's expense, to have such books and
records examined by independent certified public accountants retained by Access
and reasonably acceptable to Shaman, an independent Big 6 accounting firm shall
be deemed reasonable, during regular business hours upon reasonable advance
notice, and no more often than one time per year. Such independent accountants
shall keep confidential any information obtained during such examination and
shall report to Access only the amounts of royalties which the independent
accountant believes to be due and payable hereunder. If the accounting firm
finds an underpayment of less than 5%, Shaman shall pay such amount; if the
underpayment is greater than 5%, then Shaman shall pay such amount plus interest
at 18% plus accounting fees.
5. Due Diligence. Shaman shall use its reasonable commercial efforts to
proceed with the research, development and commercialization of Licensed
Products and shall thereafter use its reasonable commercial efforts to offer for
sale the Licensed Products so developed during the term of this Agreement.
6. Term and Termination.
6.1 Unless earlier terminated in accordance with this Section 6,
this Agreement and the licenses granted herein shall continue until the later of
(i) ten (10) years after the date such Licensed Product is first commercialized;
or (ii) the date of expiration of the last valid patent covering the
manufacture, sale or use of such Licensed Product in such country.
6.2 Access may terminate this Agreement if Shaman is: in material
breach of this Agreement and Shaman fails to remedy such breach within thirty
(30) days after written notice of breach from Access; or adjudged bankrupt or
enter into a composition with or assignment to its creditors with respect to
substantially all of its assets.
6.3 Shaman may terminate this Agreement at any time upon sixty (60)
days written notice to Access.
6.4 Exercise by either party hereto of a termination right provided
for under this Agreement shall not give rise to the payment of damages or any
other form of compensation or relief to the other party with respect hereto.
6.5 Subject to the foregoing, termination of this Agreement shall
not preclude either party from claiming any other damages, compensation or
relief that it may be entitled to under this Agreement or by law or in equity
upon such termination.
6.6 If this Agreement is terminated as set forth in this Section 6,
Shaman will: (i) renounce all rights to utilize the Access Information,
reference the Actinex NDA and utilize the Licensed Patents; and (ii) return all
Confidential Information to Access.
5.
6
6.7 The provisions of Sections 1, 4, 6, 7, 9, 10, 11, 12, 13 and 14
hereof shall survive any expiration or termination of this Agreement.
7. Arbitration.
7.1 The Parties will endeavor to settle amicably any dispute which
may arise out of this Agreement. Failing of such settlement, any dispute shall
be finally settled by arbitration, in accordance with the rules then in effect
of the American Arbitration Association. The arbitration will be held in Denver,
Colorado. The dispute or difference shall be referred to a single arbitrator, if
the Parties agree upon one, or otherwise three (3) arbitrators, one to be
appointed by each party and the third to be appointed by the first two (2)
arbitrators selected by the Parties. If a Party shall refuse or neglect to
appoint an arbitrator within thirty (30) days after the other Party shall have
served written notice of such other Party's choice and requesting that the
first-mentioned Party make its choice, then the arbitrator first appointed
shall, at the request of the Party appointing him, proceed to hear and determine
the matters in difference as if he were a single arbitrator appointed by both
parties.
7.2 The arbitrators shall base their decision in accordance with and
based upon all the provisions of this Agreement and any other agreements
referenced herein, to the extent that such other agreements are not superseded
by this Agreement or subsequent agreements between the Parties. In making their
decision, the arbitrators shall apply the substantive law of the State of
Delaware and the United States of America, excluding the United Nations
Convention on the International Sale of Goods. The decision of the majority of
the arbitrators shall be in writing and final and binding upon each Party, and
judgment upon the award may be entered in any court of competent jurisdiction.
7.3 Before rendering their final decision, the arbitrators will
first act as friendly, disinterested parties for the purpose of helping the
Parties attempt to reach a compromise settlement on the points in dispute.
7.4 The cost of arbitration will be in the discretion of the
arbitrators. Each Party shall pay its own costs associated with its arbitrator,
plus one-half the costs of the arbitration itself (including but not limited to
arbitrators fees).
7.5 Each of the parties hereto acknowledges and agrees that damages
will not be an adequate remedy for any material breach or violation of this
Agreement if such material breach or violation would cause immediate and
irreparable harm (an "Irreparable Breach"). Accordingly, notwithstanding the
provisions of Section 7.1, in the event of a threatened or ongoing Irreparable
Breach, each Party hereto shall be entitled to seek, in any court of competent
jurisdiction, equitable relief of a kind appropriate in light of the nature of
the ongoing threatened Irreparable Breach, which relief may include, without
limitation, specific performance or injunctive relief, provided, however, that
if the Party bringing such action is unsuccessful in obtaining the relief
sought, the moving party shall pay the non-moving Party's reasonable costs,
including attorney's fees, incurred in connection with defending such action.
6.
7
Such remedies shall not be the Parties' exclusive remedies, but shall be in
addition to all other remedies provided in this Agreement.
8. Exchange of Data.
8.1 Promptly after the execution of this Agreement and from time to
time thereafter during the term of this Agreement, Access shall disclose to
Shaman all relevant additional data possessed by Access generated on Masopracol
or its analogues which is necessary or helpful for Shaman or its sublicensees:
(i) to obtain the NDA approvals or other governmental approvals to market the
Licensed Products; (ii) to manufacture Licensed Products; and (iii) to generally
fulfill the purposes of this Agreement.
8.2 During the term of this Agreement, Shaman may use any data
disclosed by Access to Shaman hereunder for the purpose of developing Licensed
Products without any additional payment.
9. Trademarks and Trade Names.
9.1 Shaman and its sublicensees shall choose and own all trademarks
and trade names which are specific to the individual Licensed Products.
9.2 Product specific trademarks will be applied for and maintained
by Shaman in the Territory and all costs associated therewith shall be borne by
Shaman.
10. Confidentiality.
10.1 Access and Shaman shall keep any technology, formula, trade
secrets, technical data or business information ("Information") provided or made
available to it by the other party or its Affiliates hereunder confidential, and
neither Access nor Shaman shall, without the prior written consent of the other
party or its Affiliates, as the case may be, use (except as expressly permitted
by this Agreement or for the purposes of this Agreement), or disclose to any
third party, any Information provided or made available by the other party or
its Affiliates hereunder; provided, however, that the foregoing shall not apply
to information which the party receiving such information can establish by
written documentation to (i) have been publicly known at the time of disclosure
by the other party or its Affiliates, as the case may be, (ii) have become
publicly known, without fault on its part, subsequent to such disclosure, (iii)
have been otherwise known by it from a source (other than the other party or its
agents or Affiliates), lawfully having possession of such information, or (iv)
have been developed by it or its Affiliates independently of the disclosure by
the other party or its Affiliates.
The foregoing shall not preclude the disclosure of information by
Access or Shaman:
7.
8
(a) to its legal representatives, Affiliates, consultants, outside
contractors and (if it has the right to grant the license or sublicense) its
licensees and sublicensees, under like confidentiality obligations on the part
of the recipients, or
(b) to the extent required by law or regulation, provided that, to
the extent reasonably possible, it shall give prompt written notice of the
proposed disclosure to the other party or its Affiliates, as the case may be, so
as to allow the other party or its Affiliates, as the case may be, an
opportunity to object to such requirement and, if applicable, assure that
confidential treatment will be accorded to such information, or
(c) to the extent that such information is reasonably required to be
disclosed for the purpose of securing necessary governmental authorization for
the clinical testing or marketing of products or for the purpose of conducting
clinical testing or marketing of products, or of prosecuting or defending
litigation, or
(d) at any time following the date which is five (5) years after the
date of any termination of this Agreement.
11. Patents.
11.1 Filing for, prosecuting and maintaining patent applications and
patents included within the Patent Rights shall be the primary responsibility of
Shaman, however, in the event that Shaman fails to take any action with respect
to any such Patents Rights within 30 days after a written request from Access,
then Access shall be entitled to take such action on Shaman's behalf. Shaman and
Access shall cooperate in determining the appropriate strategy for seeking such
patent protection, including the right to review future patent applications and
related documents associated with the Patent Rights. Access shall cooperate with
and assist Shaman in filing for and prosecution of such Patent Rights. Shaman
shall keep Access reasonably informed as to the status of such Patent Rights. In
addition, Shaman will use best efforts to advise Access of all proposed patent
filings of a substantive nature in time reasonably sufficient for Access to
obtain review of such filings. Shaman shall bear all costs incurred in seeking
and maintaining patent protection of the Patent Rights.
11.2 Each party shall promptly inform the other of any suspected or
threatened infringement of any Patent Rights or Access Technology by a third
party and cooperate to develop an appropriate response to the infringement.
Access and Shaman each shall have the right to institute an action for
infringement of the Patent Rights or Access Technology against such third party.
12. Indemnity. Shaman agrees to indemnify, hold harmless and defend
Access, its officers, employees, and agents, against any and all claims, suits,
losses, damage, costs, fees, and expenses asserted by third parties, both
government and private, for death, illness, personal injury and property damage
or any other claim resulting from or arising out of (i) Shaman's, its affiliates
or sublicensees, development, advertisement, use or sale of the
8.
9
Licensed Products, (ii) breach of this Agreement, or (iii) negligence, reckless
or willful misconduct of Shaman or is affiliates, officers, employees, agents
and sublicensees, provided that Shaman shall not be responsible for amounts paid
in settlement of any claim without its approval. Access agrees to indemnify,
hold harmless and defend Shaman, its officers, directors, employees, agents and
sublicensees, against any and all claims, suits, losses, damage, costs, fees,
and expenses asserted by third parties, both government and private, resulting
from: negligence, recklessness or willful misconduct of Access, its officers,
employees and agents.
IN NO EVENT SHALL EITHER PARTY HAVE ANY LIABILITY FOR ANY SPECIAL, INDIRECT OR
CONSEQUENTIAL DAMAGES INCLUDING, WITHOUT LIMITATION, DAMAGES FOR LOST PROFITS,
LOSS OF DATA OR COSTS OF PROCUREMENT OF SUBSTITUTE GOODS OR SERVICES, ARISING IN
ANY WAY OUT OF THIS AGREEMENT UNDER ANY CAUSE OF ACTION, WHETHER OR NOT SUCH
PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES. THESE LIMITATIONS
SHALL APPLY NOTWITHSTANDING THE FAILURE OF THE ESSENTIAL PURPOSE OF ANY LIMITED
REMEDY.
13. Warranties. Access warrants that it: has the lawful right to grant
the licenses provided in this Agreement; has not granted rights or licenses in
derogation of this Agreement; has not received any notice of a claim of
infringement or misappropriation of any alleged rights asserted by any third
party in relation to the Access Information, the Access Technology or the Patent
Rights; and, except as disclosed to Shaman, Access is not aware, without having
made any investigation whatsoever, of any patents or other proprietary rights of
any third party which would materially affect the exercise of the license rights
granted hereunder to Shaman. Access agrees that during the term of this
Agreement (or any license granted hereunder), Access shall not enter into any
other agreements that conflict with rights or obligations provided hereunder,
including any rights and obligations that survive termination hereof.
WARRANTY LIMITATION, EXCEPT AS EXPRESSLY SET FORTH IN THIS AGREEMENT, ACCESS
MAKES NO REPRESENTATIONS OR WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED,
INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A
PARTICULAR PURPOSE OR WITH RESPECT TO (1) THE SCOPE OF VALIDITY OF ANY OF THE
PATENT RIGHTS; (2) WHETHER THE PATENT RIGHTS OR TECHNOLOGY MAY BE EXPLOITED BY
SHAMAN OR ANY SUBLICENSEE WITHOUT INFRINGING THE RIGHTS (INCLUDING PATENT
RIGHTS) OF OTHERS; OR (3) THE RESULTS TO BE OBTAINED BY USE OF THE PATENT
RIGHTS, THE ACCESS PRODUCTS. THE PATENT RIGHTS, ACCESS TECHNOLOGY AND ACCESS
INFORMATION ARE DELIVERED "AS IS" IN EVERY RESPECT.
9.
10
14. Miscellaneous.
14.1 Governing Law. This Agreement shall be governed by and
construed in accordance with the laws of the State of Delaware without regard to
the conflict of laws provisions thereof.
14.2 Severability. If any provision of this Agreement is held to be
invalid by a court of competent jurisdiction, then the remaining provisions
shall nevertheless remain in full force and effect. The parties further agree to
negotiate in good faith a substitute, valid and enforceable provision that most
nearly effects the parties' intent and to be bound by mutually agreed substitute
provision.
14.3 Waiver. It is agreed that no waiver by either party hereto of
any breach or default of any of the covenants or agreements herein set forth
shall be deemed a waiver as to any subsequent and/or similar breach or default.
14.4 Force Majeure. Nonperformance of either party shall be excused
to the extent that performance is rendered impossible by strike, fire, flood,
governmental acts or orders or restrictions, failure of suppliers, or any other
reason where failure to perform is beyond the reasonable control and not caused
by the negligence of the nonperforming party.
14.5 Successors and Assigns. This Agreement shall be binding upon
and shall inure to the benefit of, successors and assigns of each of the
Parties, but neither this Agreement nor any of the rights, interests or
obligations hereunder may be assigned by either of the Parties hereto without
the prior written consent of the other Party, which consent shall not be
unreasonably withheld; provided that this Agreement may be assigned in the event
of a transfer to an Affiliate, or in connection with a merger, consolidation, or
sale of substantially all of the assets of the transferring party.
Notwithstanding anything to the contrary herein, Access may delegate to its
Affiliates its duties and obligations hereunder without the consent of Shaman.
14.6 Independent Contractors. The relationship of Access and Shaman
established by this Agreement is that of independent contractors, and nothing
contained in this Agreement shall be construed (i) to give either party the
power to direct or control the day-to-day activities of the other or (ii) to
constitute the parties as partners, joint venturers, co-owners or otherwise as
participants in a joint or common undertaking.
14.7 Captions. The captions provided in this Agreement are for the
convenience of reference only and shall not effect its interpretation.
14.8 Entire Agreement. This Agreement constitutes the entire, final,
complete and exclusive agreement between the parties and supersedes all previous
agreements or representations, oral or written, relating to this Agreement. This
Agreement may not be modified or amended except in a writing signed by a duly
authorized representative of each
10.
11
party. Both parties acknowledge having read the terms and conditions set forth
in this Agreement, understand all terms and conditions, and agree to be bound
thereby.
14.9 Notices. Any notice required or permitted to be given to the
parties hereto shall be deemed to have been properly given if delivered in
person or when received if mailed by first-class certified mail to the other
party at the appropriate address set forth below, or to such other addresses as
may be designated in writing by the parties from time to time during the term of
this Agreement.
If to Access: Access Pharmaceuticals, Inc.
▇▇▇▇ ▇▇▇▇▇ ▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇, ▇▇▇▇▇ ▇▇▇
▇▇▇▇▇▇, ▇▇▇▇▇ ▇▇▇▇▇
Attention: President and CEO
Copy to: ▇▇▇▇▇▇▇, ▇▇▇▇ and ▇▇▇▇▇ LLP
▇▇▇ ▇▇▇▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇▇▇, ▇▇▇▇▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇-▇▇▇▇
Attention: ▇▇▇▇ ▇▇▇▇▇▇▇▇▇ III
If to Shaman: Shaman Pharmaceuticals, Inc.
▇▇▇ ▇▇▇▇ ▇▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇▇ ▇▇▇ ▇▇▇▇▇▇▇▇▇, ▇▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇-▇▇▇▇
Attention: President and CEO
Copy to: ▇▇▇▇▇▇▇, ▇▇▇▇▇▇▇ & ▇▇▇▇▇▇▇▇ LLP
Attention: ▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇
Two Embarcadero Place
▇▇▇▇ ▇▇▇▇ ▇▇▇▇
▇▇▇▇ ▇▇▇▇, ▇▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇
11.
12
IN WITNESS WHEREOF, the parties have caused this Agreement to be
executed by their duly authorized representatives as of the day and year first
written above.
SHAMAN PHARMACEUTICALS, INC. ACCESS PHARMACEUTICALS, INC.
By: /s/ ▇▇▇▇ ▇. ▇▇▇▇▇ By: /s/ ▇▇▇▇▇ ▇. ▇▇▇▇
----------------------- ------------------------
Name: ▇▇▇▇ ▇. ▇▇▇▇▇ Name: ▇▇▇▇▇ ▇. ▇▇▇▇
----------------------- ------------------
Title:President & CEO Title: President & CEO
---------------------- ---------------------
12.
13
EXHIBIT A
ACCESS INFORMATION
1. The following studies and sections of the Actinex(TM) New Drug
Application ("NDA") and New Drug Submission - Canada ("NDS"):
a. NDA Pharmacology summary
b. NDS Pharmacology summary
c. NDS CMS Section
d. T005-89 - ▇▇▇▇ Test - CHX 100 - Summary & Report
e. T003-87 Acute Oral Rat Tox - CHX 100 - Summary & Report
f. T004-87 Acute Oral Rabbit Tox - CHX 100 - Summary & Report
g. T004-89 - Target Organ Oral Rat Tox - CHX 100 - Summary &
Report
h. T004-89 - Oral Segment II - Rat - CHX 100 - Summary & Report
i. T009-89 - Oral Rabbit Dose Finding Segment II - CHX 100 -
Summary & Report
j. T001-90 - Oral Rabbit Segment II - CHX 100 - Summary & Report
k. K001-84 - Rat Biodistribution, Oral, Intravenous and Dermal -
CHX 100 - Summary & Report
2. Oral mass balance studies on CHX 100 conducted by Chemex or Access.
3. Access will provide reports of Segment I & III reproductive safety
studies on CHX 100.
